Trial Profile
Phase II study of erlotinib (Tarceva) and radiotherapy for elderly patients with esophageal carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 28 Oct 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
- 28 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2011 Planned End Date changed from 1 Oct 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.